Status:

COMPLETED

Studies Investigating Co-morbidities Aggravating Heart Failure

Lead Sponsor:

Charite University, Berlin, Germany

Collaborating Sponsors:

University of Hull

Wroclaw Medical University

Conditions:

Heart Failure

Type 2 Diabetes Mellitus

Eligibility:

All Genders

18+ years

Brief Summary

SICA-HF is a prospective, multicentre, multinational, longitudinal, pathophysiological evaluation study, which is being conducted in 11 centres across six countries. SICA-HF receives funding from the ...

Detailed Description

SICA-HF, consisting of outstanding European heart failure clinicians and basic researchers, has accomplished to provide a common platform for the two different research teams. All partners of SICA-HF ...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Clinical diagnosis of heart failure;
  • Objective evidence of cardiac dysfunctions as evidenced by at least ONE of the following:
  • left ventricular ejection fraction ≤ 40%;
  • left atrial dimension \>4.0 cm (or \>2.5 cm/m in height)
  • NT-proBNP \>400 pg/ml \[\>47.3 pmol/l\] (or BNP \>150 pg/ml)
  • Current treatment with loop diuretics;
  • Age \>18 years;
  • Willingness to provide informed consent
  • Exclusion criteria:
  • Congenital heart disease;
  • Any life-threatening disease other than heart failure;
  • Active malignancy of any type, or history of a malignancy within previous 5 years;
  • Previous heart transplantation;
  • Intra-venous therapy for heart failure given within the previous 72 hours;
  • Severe neuro-muscular disease;
  • History of unstable angina, myocardial infarction or stroke within 3 months prior to the study;
  • Pregnancy;
  • Treatment with immunosuppressive therapy, e.g. steroids for rheumatoid arthritis or obstructive lung disease;
  • Significant renal dysfunction, defined as serum creatinine \>250 μmol/L \[\>2.8 mg/dL\];
  • Severe liver disease, defined as any liver function tests \>3 times the upper limit of normal;
  • Unable to understand and comply with protocol or to give informed consent.

Exclusion

    Key Trial Info

    Start Date :

    March 1 2010

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    July 1 2016

    Estimated Enrollment :

    1600 Patients enrolled

    Trial Details

    Trial ID

    NCT01872299

    Start Date

    March 1 2010

    End Date

    July 1 2016

    Last Update

    July 26 2016

    Active Locations (11)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (11 locations)

    1

    Hannover Medical School

    Hanover, Hannover, Germany, 30625

    2

    Charité- University Medicine Berlin, Campus Virchow Klinikum

    Berlin, State of Berlin, Germany, 13353

    3

    IRCCS San Raffaele

    Rome, Rom, Italy, 00163

    4

    Wroclaw, Medical University

    Wroclaw, Wroclaw, Poland, 50-367

    Studies Investigating Co-morbidities Aggravating Heart Failure | DecenTrialz